4 completed, 1 terminated. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow INGAP peptide: new trials by email Literature Review of INGAP peptide trials Research Report on INGAP peptide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis INGAP Peptide, Ustekinumab - Type 1 Diabetes Mellitus | Phase 2 | Completed | Jewish General Hospital | 5 | 2015-11-01 | 2017-05-30 |
| Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults INGAP Peptide, Placebo - Type 1 Diabetes Mellitus | Phase 2 | Terminated | Exsulin Corporation | 23 | 2009-11-01 | 2014-02-12 |
| Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes INGAP-Peptide, placebo - Diabetes Mellitus, Insulin-Dependent | Phase 2 | Completed | Exsulin Corporation | 63 | 2003-10-01 | 2014-07-11 |
| Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes INGAP-Peptide, placebo - Diabetes Mellitus, Non-Insulin-Dependent | Phase 2 | Completed | Exsulin Corporation | 126 | 2003-10-01 | 2014-07-11 |
| Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients INGAP Peptide - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 1 / Phase 2 | Completed | GMP Endotherapeutics | 62 | 2001-12-01 | 2005-06-24 |
Diabetes Mellitus, Type 1 (4) · Diabetes Mellitus, Type 2 (2)
Exsulin Corporation (3) · GMP Endotherapeutics (1) · Jewish General Hospital (1)
United States (4) · Canada (2)
George Tsoukas, MD (2) · Yogish Kudva, M.D. (1)